葛兰素史克盘前涨超2%在日本获得支气管哮喘治疗的监管批准

动脉网
Jan 06

葛兰素史克1月6日盘前股价涨超2%,报50.08美元。消息面上,其用于治疗支气管哮喘及伴鼻息肉慢性鼻窦炎的药物Exdensur(通用名:depemokimab)在日本获得监管批准。该药物此前已在美国和英国获批上市,目前正在包括中国在内的其他多个市场接受监管审查。此次日本获批,意味着葛兰素史克在拓展Exdensur市场方面取得新进展,不仅为日本当地支气管哮喘及伴鼻息肉慢性鼻窦炎患者带来新治疗选择,也...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10